Scandion Oncology Future Growth
Future criteria checks 2/6
Scandion Oncology is forecast to grow earnings and revenue by 69.7% and 39.5% per annum respectively. EPS is expected to grow by 106.9% per annum. Return on equity is forecast to be -60.3% in 3 years.
Key information
69.7%
Earnings growth rate
106.9%
EPS growth rate
| Biotechs earnings growth | 44.9% |
| Revenue growth rate | 39.5% |
| Future return on equity | -60.3% |
| Analyst coverage | Low |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully
Aug 02
Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth
Feb 01Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation
May 26We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely
Jan 06
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -4 | -4 | -4 | 1 |
| 12/31/2025 | 13 | -10 | -10 | -10 | 1 |
| 12/31/2024 | N/A | -27 | -23 | -23 | 1 |
| 9/30/2024 | N/A | -32 | -36 | -36 | N/A |
| 6/30/2024 | N/A | -36 | -33 | -33 | N/A |
| 3/31/2024 | N/A | -37 | -43 | -43 | N/A |
| 12/31/2023 | N/A | -39 | -51 | -51 | N/A |
| 9/30/2023 | N/A | -44 | -54 | -54 | N/A |
| 6/30/2023 | N/A | -59 | -69 | -69 | N/A |
| 3/31/2023 | N/A | -73 | -69 | -69 | N/A |
| 12/31/2022 | N/A | -77 | -70 | -69 | N/A |
| 9/30/2022 | N/A | -76 | -68 | -67 | N/A |
| 6/30/2022 | N/A | -66 | -57 | -57 | N/A |
| 3/31/2022 | N/A | -56 | -57 | -56 | N/A |
| 12/31/2021 | N/A | -52 | -50 | -50 | N/A |
| 9/30/2021 | N/A | -43 | -48 | -48 | N/A |
| 6/30/2021 | N/A | -31 | -34 | -34 | N/A |
| 3/31/2021 | N/A | -22 | -24 | -24 | N/A |
| 12/31/2020 | N/A | -17 | -17 | -17 | N/A |
| 9/30/2020 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -14 | -14 | -14 | N/A |
| 3/31/2020 | N/A | -14 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -12 | -10 | -10 | N/A |
| 9/30/2019 | N/A | -17 | -21 | -21 | N/A |
| 6/30/2019 | N/A | -12 | -16 | -16 | N/A |
| 3/31/2019 | N/A | -10 | -15 | -15 | N/A |
| 12/31/2018 | N/A | -8 | -13 | -13 | N/A |
| 9/30/2018 | N/A | -4 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCOL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SCOL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SCOL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SCOL's revenue (39.5% per year) is forecast to grow faster than the Swedish market (-0.04% per year).
High Growth Revenue: SCOL's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SCOL is forecast to be unprofitable in 3 years.